Portal vein-circulating tumor cells predict liver metastases in patients with resectable pancreatic cancer

Tumor Biology

Volumn 36, Issue 2, 2015, Pages 991-996

  Bissolati, Massimiliano ^a   Sandri, Maria Teresa ^b   Burtulo, Giovanni ^a   Zorzino, Laura ^b   Balzano, Gianpaolo ^a   Braga, Marco ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Circulating tumor cells; Liver metastases; Pancreatic cancer; Portal vein; Surgery

Indexed keywords

GEMCITABINE;

ADJUVANT THERAPY; AGED; ARTICLE; BLOOD SAMPLING; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; INTRAOPERATIVE PERIOD; LIVER METASTASIS; MALE; PANCREAS CANCER; PILOT STUDY; PORTAL VEIN; PREDICTIVE VALUE; PRIORITY JOURNAL; SYSTEMIC CIRCULATION; LIVER; LIVER NEOPLASMS; METASTASIS; MIDDLE AGED; PANCREATIC NEOPLASMS; PATHOLOGY; PROGNOSIS; SECONDARY; TUMOR EMBOLISM;

AGED; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PANCREATIC NEOPLASMS; PORTAL VEIN; PROGNOSIS;

EID: 84925498027     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2716-0     Document Type: Article

References (34)

1. Baschnagel A, Shah C, Margolis J, Nadeau L, Stein J, Jury R, et al. Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine. Int J Radiat Oncol Biol Phys. 2012;83:e331–5.
2. Miller RC, Iott MJ, Corsini MM. Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposium. Int J Radiat Oncol Biol Phys. 2009;75:364–8.
3. Hattangadi JA, Hong TS, Yeap BY, Mamon HJ. Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma. Cancer. 2009;115:3640–50.
4. Van den Broeck A, Sergeant G, Ectors N, Van Steenbergen W, Aerts R, Topal B. Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol. 2009;35:600–4.
5. Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K, Igarashi S. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg. 2006;10:511–8.
6. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–91.
7. Cristofanilli M. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. Semin Oncol. 2006;33:S9–14.
8. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:3213–21.
9. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol. 2009;20:1223–9.
10. Groot Koerkamp B, Rahbari NN, Büchler MW, Koch M, Weitz J. Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: a meta-analysis. Ann Surg Oncol. 2013;20:2156–65.
11. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14:6302–9.
12. Doyen J, Alix-Panabières C, Hofman P, Parks SK, Chamorey E, Naman H, et al. Circulating tumor cells in prostate cancer: a potential surrogate marker of survival. Crit Rev Oncol Hematol. 2012;81:241–56.
13. Hou JM, Greystoke A, Lancashire L, Cummings J, Ward T, Board R, et al. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol. 2009;175:808–16.
14. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol. 2011;29:1556–63.
15. Pierga JY, Bidard FC, Mathiot C, Brain E, Delaloge S, Giachetti S, et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res. 2008;14:7004–10.
16. Bidard FC, Belin L, Delaloge S, Lerebours F, Ngo C, Reyal F, et al. Time-dependent prognostic impact of circulating tumor cells detection in non-metastatic breast cancer: 70-month analysis of the REMAGUS02 study. Int J Breast Cancer. 2013;2013:130470.
17. Karhade M, Hall C, Mishra P, Anderson A, Kuerer H, Bedrosian I, et al. Circulating tumor cells in non-metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2014;147:325–33.
18. Rack B, Schindlbeck C, Jückstock J, Andergassen U, Hepp P, Zwingers T, SUCCESS Study Group, et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst. 2014;106(5). doi:10.1093/jnci/dju066
19. Gazzaniga P, de Berardinis E, Raimondi C, Gradilone A, Busetto GM, De Falco E, et al. Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer. Int J Cancer. 2014;135:1978–82.
20. Thorsteinsson M, Jess P. The clinical significance of circulating tumor cells in non-metastatic colorectal cancer—a review. Eur J Surg Oncol. 2011;37:459–65.
21. Urtishak S, Alpaugh RK, Weiner LM, Swaby RF. Clinical utility of circulating tumor cells: a role for monitoring response to therapy and drug development. Biomark Med. 2008;2:137–45.
22. Uchikura K, Takao S, Nakajo A, Miyazono F, Nakashima S, Tokuda K, et al. Intraoperative molecular detection of circulating tumor cells by reverse transcription-polymerase chain reaction in patients with biliary-pancreatic cancer is associated with hematogenous metastasis. Ann Surg Oncol. 2002;9:364–70.
23. Soeth E, Grigoleit U, Moellmann B, Röder C, Schniewind B, Kremer B, et al. Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival. J Cancer Res Clin Oncol. 2005;131:669–76.
24. Sergeant G, Roskams T, van Pelt J, Houtmeyers F, Aerts R, Topal B. Perioperative cancer cell dissemination detected with a real-time RT-PCR assay for EpCAM is not associated with worse prognosis in pancreatic ductal adenocarcinoma. BMC Cancer. 2011;11:47.
25. Kurihara T, Itoi T, Sofuni A, Itokawa F, Tsuchiya T, Tsuji S, et al. Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result. J Hepatobiliary Pancreat Surg. 2008;15:189–95.
26. Bidard FC, Huguet F, Louvet C, Mineur L, Bouché O, Chibaudel B, et al. Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. Ann Oncol. 2013;24:2057–61.
27. Khoja L, Backen A, Sloane R, Menasce L, Ryder D, Krebs M, et al. A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer. 2012;106:508–16.
28. Han L, Chen W, Zhao Q. Prognostic value of circulating tumor cells in patients with pancreatic cancer: a meta-analysis. Tumour Biol. 2014;35(3):2473–80.
29. Kagan M, Howard D, Bendele T, Rao C, Terstappen L. Circulating tumor cells as cancer markers: a sample preparation and analysis system. Tumor markers physiology, pathobiology, technology and applications. Washington D.C.: AACC; 2003. p. 495–8. chapter 52.
30. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10:6897–904.
31. de Albuquerque A, Kubisch I, Breier G, Stamminger G, Fersis N, Eichler A, et al. Multimarker gene analysis of circulating tumor cells in pancreatic cancer patients: a feasibility study. Oncology. 2012;82:3–10.
32. Sergeant G, van Eijsden R, Roskams T, Van Duppen V, Topal B. Pancreatic cancer circulating tumour cells express a cell motility gene signature that predicts survival after surgery. BMC Cancer. 2012;12:527.
33. Zhong W, Chen W, Zhang D, Sun J, Li Y, Zhang J, et al. CXCL12/CXCR4 axis plays pivotal roles in the organ-specific metastasis of pancreatic adenocarcinoma: a clinical study. Exp Ther Med. 2012;4:363–9.
34. Tjensvoll K, Nordgård O, Smaaland R. Circulating tumor cells in pancreatic cancer patients: methods of detection and clinical implications. Int J Cancer. 2014;134:1–8.